ISOGENICA
Isogenica Limited, a biotechnology company, develops therapeutic peptides to treat diseases. The company's vitro display technology, CIS display is used to discover biologically active peptides, proteins, and antibodies. Isogenica Limited was founded in 2000 and is based in Cambridge, the United Kingdom.
ISOGENICA
Industry:
Biopharma Biotechnology Health Care Life Science
Founded:
2000-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.isogenica.com
Total Employee:
11+
Status:
Active
Contact:
+44 1799 533680
Total Funding:
9 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Employees Featured
Emma Sceats CEO @ Isogenica
CEO
2018-09-01
Anthony M. Nixon General Counsel @ Isogenica
General Counsel
Chris Ullman CSO @ Isogenica
CSO
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2008-05-06 | Karyon-CTT | Karyon-CTT acquired by Isogenica | N/A |
Investors List
Innovate UK
Innovate UK investment in Grant - Isogenica
Official Site Inspections
http://www.isogenica.com Semrush global rank: 6.93 M Semrush visits lastest month: 687
- Host name: grh70.myukcloud.com
- IP address: 5.134.14.106
- Location: United Kingdom
- Latitude: 51.4964
- Longitude: -0.1224
- Timezone: Europe/London
More informations about "Isogenica"
VHH single-domain antibodies | ISOGENICA
Isogenica announces two Pioneering Collaborations with an Antibody Research and License Agreement, and an Asset Evaluation Deal Isogenica, a leading innovator in VHH antibodies, is …See details»
Isogenica - Crunchbase Company Profile & Funding
Isogenica Limited, a biotechnology company, develops therapeutic peptides to treat diseases. The company's vitro display technology, CIS display is used to discover biologically active …See details»
Isogenica Company Profile | Management and Employees List
Isogenica is a drug discovery platform-licensing company focusing on the design and build of diverse, fully synthetic, antibody libraries for use in biopharmaceutical discovery. Partners can …See details»
Isogenica - LinkedIn
Isogenica is a bespoke biotech CRO specialised in solving antibody discovery and engineering challenges with small-format antibodies, particularly VHH single-domains.See details»
Isogenica Company Profile 2024: Valuation, Funding & Investors
Isogenica was founded in 1998. Where is Isogenica headquartered? Isogenica is headquartered in Essex, United Kingdom. What is the size of Isogenica? Isogenica has 21 total employees. …See details»
Isogenica Overview | SignalHire Company Profile
Isogenica Overview Summary. Isogenica is a bespoke biotech CRO specialised in solving antibody discovery and engineering challenges with small-format antibodies, particularly VHH …See details»
Isogenica turns 25: Our journey
May 2, 2023 Isogenica is a biotechnology company specializing in the discovery and development of small format single chain VHH antibodies. We are leaders in our domain, having developed a fully synthetic, in vitro plug-and-play cassette …See details»
Isogenica - VentureRadar
Isogenica is a biotech CRO specializing in VHH antibody discovery and engineering. Utilizing the largest and most diverse synthetic VHH libraries combined with proprietary CIS display …See details»
Isogenica Limited Information - RocketReach
Isogenica is a bespoke biotech CRO specialised in solving antibody discovery and engineering challenges with small-format antibodies, particularly VHH single-domains. Sometimes known …See details»
Isogenica turns 25: A beautiful journey - BioPartner UK
May 2, 2023 Our journey started in May 1998, when Isogenica was spun out from Swedish biotech company ActiNova. Having been initially named Pharmacophorix, the name was …See details»
Isogenica Company Profile - Office Locations, Competitors ... - Craft
Isogenica is a company that develops LlamdA VHH, versatile small-format antibodies that utilizing to construct biotherapeutics for the treatment of cancer, inflammation, and other serious …See details»
Looking for a partner in antibody discovery? - Isogenica
Partner with us for antibody discovery and experience a tailored and collaborative approach to contract research organization services. About Us. About Us; Our Team; Board of Directors; …See details»
Isogenica - Products, Competitors, Financials, Employees, …
Isogenica Photo credits: Chris Isogenica is an expert in the discovery of small-format antibodies, with a specialist focus on camelid-derived VHHs, which the company says offer exceptional …See details»
Isogenica | Scientist.com
Isogenica has 3 partnered assets into clinical development. We develop proprietary LlamdA® VHH: highly versatile small format single domain antibodies, which we use to construct next …See details»
Isogenica - Overview, News & Similar companies | ZoomInfo.com
Isogenica is a drug discovery platform-licensing company focusing on the design and build of diverse, fully synthetic, antibody libraries for use in biopharmaceutical discovery. Partners can …See details»
Contact Us - Isogenica
Isogenica Ltd The Mansion House Chesterford Research Park Little Chesterford Essex CB10 1 XL UK " Careers at Isogenica. A career at Isogenica provides an opportunity to lead, execute …See details»
Isogenica - Contacts, Employees, Board Members, Advisors
Isogenica operates a range of discovery platforms supported by state-of-the-art methodologies for identifying antibody and peptide ligands.See details»
| One Nucleus
Isogenica’s partners can access a range of innovative, highly-diverse, antibody libraries as an excellent starting point for new biotherapeutic development programmes.. . All the company’s …See details»
Partnerships with Isogenica | Global Biopharma Collaborative …
Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including two clinical assets and eight partnered pre-clinical and discovery programs. …See details»